Canada can’t afford to leave research out of the innovation conversation
To date, in the hopes of commercializing key biopharma products like vaccines, Canada has delivered significant dollars directly to companies. While this will certainly help bolster the industry—or at least elements of its operation—what’s further needed are investments in fundamental research in health and biomedicine.

Over the course of Canada’s late summer election, it was promising to see innovation featured on the agenda of our federal leaders as action is long overdue.
We’ve been hearing for too long about how Canada is underperforming on this front, and remedying it is becoming ever more necessary in a ...
SPONSORED CONTENT
Get Tuesdays: Innovation & Industry Newsletter
The policies, decisions, and people working on investment and regulation in the industry and innovation realm.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy












